Receptor BioLogix, headquartered in Palo Alto, California, specializes in the development of receptor-based biological therapeutics for cancer, inflammatory, and autoimmune diseases. Their main focus is on the newly discovered class of protein therapeutics called Intron Fusion Proteins (IFP), which have the potential to revolutionize treatment options for these diseases. By leveraging their expertise in this field, Receptor BioLogix aims to bring innovative and effective therapies to patients in need.